Publications

Filters: First Letter Of Keyword is A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Reich, Brian J., and Howard D. Bondell. "A spatial dirichlet process mixture model for clustering population genetics data." Biometrics 67, no. 2 (2011): 381-90.
Owzar, Kouros, William T. Barry, and Sin-Ho Jung. "Statistical considerations for analysis of microarray experiments." Clin Transl Sci 4, no. 6 (2011): 466-77.
Kimes, Patrick K., Yufeng Liu, David Neil Hayes, and James Stephen Marron. "Statistical significance for hierarchical clustering." Biometrics 73, no. 3 (2017): 811-821.
Kang, Suhyun, Wenbin Lu, and Rui Song. "Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659.
Kang, Suhyun, Wenbin Lu, and Rui Song. "Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659.
Vock, David M., Michael T. Durheim, Wayne M. Tsuang, Ashley Finlen C Copeland, Anastasios A. Tsiatis, Marie Davidian, Megan L. Neely, David J. Lederer, and Scott M. Palmer. "Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation." Ann Am Thorac Soc 14, no. 2 (2017): 172-181.
Love, Michael I., Charlotte Soneson, and Rob Patro. "Swimming downstream: statistical analysis of differential transcript usage following Salmon quantification." F1000Res 7 (2018): 952.
Wilson, Florence R., Abhishek Varu, Debanjali Mitra, Chris Cameron, and Shrividya Iyer. "Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
Wilson, Florence R., Abhishek Varu, Debanjali Mitra, Chris Cameron, and Shrividya Iyer. "Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
T
Zhang, Xiang, Shunping Huang, Fei Zou, and Wei Wang. "TEAM: efficient two-locus epistasis tests in human genome-wide association study." Bioinformatics 26, no. 12 (2010): i217-27.
Kass, Robert E., Brian S. Caffo, Marie Davidian, Xiao-Li Meng, Bin Yu, and Nancy Reid. "Ten Simple Rules for Effective Statistical Practice." PLoS Comput Biol 12, no. 6 (2016): e1004961.
Samsky, Marc D., Chetan B. Patel, Ashleigh Owen, Phillip J. Schulte, Jacob Jentzer, Paul B. Rosenberg, Michael G Felker, Carmelo A. Milano, Adrian F. Hernandez, and Joseph G. Rogers. "Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
Samsky, Marc D., Chetan B. Patel, Ashleigh Owen, Phillip J. Schulte, Jacob Jentzer, Paul B. Rosenberg, Michael G Felker, Carmelo A. Milano, Adrian F. Hernandez, and Joseph G. Rogers. "Ten-year experience with extended criteria cardiac transplantation." Circ Heart Fail 6, no. 6 (2013): 1230-8.
Kong, Dehan, Arnab Maity, Fang-Chi Hsu, and Jung-Ying Tzeng. "Testing and estimation in marker-set association study using semiparametric quantile regression kernel machine." Biometrics 72, no. 2 (2016): 364-71.
Olby, Natasha J., Ji-Hey Lim, Nikki Wagner, Natalia Zidan, Peter J. Early, Christopher L. Mariani, Karen R. Muñana, and Eric Laber. "Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion." J Vet Intern Med 33, no. 2 (2019): 726-734.
Zhu, Zhaoyin, Xiaofei Wang, Paramita Saha-Chaudhuri, Andrzej S. Kosinski, and Stephen L. George. "Time-dependent classification accuracy curve under marker-dependent sampling." Biom J 58, no. 4 (2016): 974-92.
Cai, Na, Wenbin Lu, and Hao Helen Zhang. "Time-varying latent effect model for longitudinal data with informative observation times." Biometrics 68, no. 4 (2012): 1093-102.
Freedman, Rachel A., Rebecca S. Gelman, Jeffrey S. Wefel, Michelle E. Melisko, Kenneth R. Hess, Roisin M. Connolly, Catherine H. Van Poznak, Polly A. Niravath, Shannon L. Puhalla, Nuhad Ibrahim et al. "Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
Freedman, Rachel A., Rebecca S. Gelman, Jeffrey S. Wefel, Michelle E. Melisko, Kenneth R. Hess, Roisin M. Connolly, Catherine H. Van Poznak, Polly A. Niravath, Shannon L. Puhalla, Nuhad Ibrahim et al. "Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
Caron, Whitney P., John C. Lay, Alan M. Fong, Ninh M. La-Beck, Parag Kumar, Suzanne E. Newman, Haibo Zhou, Jane H. Monaco, Daniel L. Clarke-Pearson, Wendy R. Brewster et al. "Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology." J Pharmacol Exp Ther 347, no. 3 (2013): 599-606.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Diéras, Véronique, David Miles, Sunil Verma, Mark Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim Blackwell, Silke Hoersch, Jin Xu et al. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol 18, no. 6 (2017): 732-742.
Li, Yimei, John H. Gilmore, Jiaping Wang, Martin Styner, Weili Lin, and Hongtu Zhu. "TwinMARM: two-stage multiscale adaptive regression methods for twin neuroimaging data." IEEE Trans Med Imaging 31, no. 5 (2012): 1100-12.
Love, Michael I., Charlotte Soneson, Peter F. Hickey, Lisa K. Johnson, Tessa N Pierce, Lori Shepherd, Martin Morgan, and Rob Patro. "Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
Love, Michael I., Charlotte Soneson, Peter F. Hickey, Lisa K. Johnson, Tessa N Pierce, Lori Shepherd, Martin Morgan, and Rob Patro. "Tximeta: Reference sequence checksums for provenance identification in RNA-seq." PLoS Comput Biol 16, no. 2 (2020): e1007664.
V
Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke et al. "Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke et al. "Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke et al. "Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist 22, no. 2 (2017): 189-198.
Wang, Xiaofei, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, Harvey Jay Cohen, Thomas Stinchcombe, Everett Vokes et al. "Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups." Lung Cancer 90, no. 2 (2015): 281-7.
Yuan, Shuai, Hao Helen Zhang, and Marie Davidian. "Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials." Stat Med 31, no. 29 (2012): 3789-804.
Zhou, Jie, Jiajia Zhang, Alexander C. Mclain, Wenbin Lu, Xuemei Sui, and James W. Hardin. "A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality." Biometrics 75, no. 3 (2019): 853-863.
Zhou, Jie, Jiajia Zhang, Alexander C. Mclain, Wenbin Lu, Xuemei Sui, and James W. Hardin. "A varying-coefficient generalized odds rate model with time-varying exposure: An application to fitness and cardiovascular disease mortality." Biometrics 75, no. 3 (2019): 853-863.

Pages